Hypogonadism causes bone loss and increased bone metastases in a model of mixed osteolytic/osteoblastic metastases: Prevention by zoledronic acid

被引：0
|
作者：
Padalecki, SS [1 ]
Carreon, M [1 ]
Grubbs, B [1 ]
Guise, TA [1 ]
机构：
[1] Univ Texas, Hlth Sci Ctr, San Antonio, TX 78285 USA
来源：
JOURNAL OF BONE AND MINERAL RESEARCH | 2004年 / 19卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1589 / 1590
页数：2
相关论文
共 50 条
  • [1] Hypogonadism causes bone loss and increased bone metastasesin a model of mixed osteolytic/osteoblastic metastases: Prevention by zoledronic acid.
    Padalecki, SS
    Carreon, MR
    Grubbs, BG
    Guise, TA
    JOURNAL OF BONE AND MINERAL RESEARCH, 2003, 18 : S36 - S36
  • [2] Prevention and treatment of hypogonadism-associated bone loss and bone metastases by OPG-Fc in a model of mixed osteolytic/osteoblastic metastases
    Padalecki, S. S.
    Grubbs, B.
    Goins, B.
    Soundarajan, A.
    Mundy, G. R.
    Dougall, W.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2007, 22 : S115 - S115
  • [3] Androgen deprivation causes bone loss and increased prostate cancer metastases to bone: Prevention by zoledronic acid.
    Padalecki, SS
    Carreon, MR
    Grubbs, B
    Cui, Y
    Guise, TA
    JOURNAL OF BONE AND MINERAL RESEARCH, 2002, 17 : S310 - S310
  • [4] Differences of osteoblastic bone metastases and osteolytic bone metastases in clinical features and molecular characteristics
    Fang, J.
    Xu, Q.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2015, 17 (03): : 173 - 179
  • [5] Differences of osteoblastic bone metastases and osteolytic bone metastases in clinical features and molecular characteristics
    J. Fang
    Q. Xu
    Clinical and Translational Oncology, 2015, 17 : 173 - 179
  • [6] Basic mechanisms responsible for osteolytic and osteoblastic bone metastases
    Guise, Theresa A.
    Mohammad, Khalid S.
    Clines, Gregory
    Stebbins, Elizabeth G.
    Wong, Darren H.
    Higgins, Linda S.
    Vessella, Robert
    Corey, Eva
    Padalecki, Susan
    Suva, Larry
    Chirgwin, John M.
    CLINICAL CANCER RESEARCH, 2006, 12 (20) : 6213S - 6216S
  • [7] Zoledronic acid for the prevention of bone metastases in patients with breast cancer
    Coleman, R.
    Gralow, J.
    Bell, R.
    Lipton, A.
    EJC SUPPLEMENTS, 2004, 2 (03): : 74 - 75
  • [8] Characterization of osteoblastic and osteolytic proteins in prostate cancer bone metastases
    Larson, Sandy R.
    Zhang, Xiaotun
    Dumpit, Ruth
    Coleman, Ilsa
    Lakely, Bryce
    Roudier, Martine
    Higano, Celestia S.
    True, Lawrence D.
    Lange, Paul H.
    Montgomery, Bruce
    Corey, Eva
    Nelson, Peter S.
    Vessella, Robert L.
    Morrissey, Colm
    PROSTATE, 2013, 73 (09): : 932 - 940
  • [9] Responsiveness of osteoblastic and osteolytic bone metastases to vitamin D analogs
    Peleg, Sara
    CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION, 2007, 17 (02): : 149 - 158
  • [10] The identification of osteoblastic and osteolytic factors in prostate cancer bone metastases
    Zhang, Xiaotun
    Larson, Sandy
    Dumpit, Ruth
    Coleman, Ilsa
    Lakely, Bryce
    Roudier, Martine
    Higano, Celestia
    True, Lawrence D.
    Lange, Paul H.
    Nelson, Peter S.
    Corey, Eva
    Vessella, Robert L.
    Morrissey, Colm
    CANCER RESEARCH, 2012, 72
12345